Conditions: Type 2 Diabetes
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 13
Healthy volunteers: no

Brief summary:
This study will evaluate the safety and tolerability of single doses of MK-0941 based on assessment of clinical and laboratory adverse experiences

Detailed description:

Arms:
arm 1: Period 1: Placebo - Period 2: 80 mg - Period 3: 100 mg - Period 4: Placebo - Period 5: 140 mg arm 2: Period 1: 60 mg - Period 2: 80 mg - Period 3: 100 mg - Period 4: 120 mg - Period 5: Placebo arm 3: Period 1: 60 mg - Period 2: Placebo - Period 3: 100 mg - Period 4: 120 mg - Period 5: 140 mg arm 4: Period 1: 60 mg - Period 2: 80 mg - Period 3: Placebo - Period 4: 120 mg - Period 5: 140 mg

Interventions: intervention 1: MK-0941 intervention 2: Comparator: Placebo
Intervention descriptions: intervention 1: A single 60, 80, 100, 120 or 140 mg oral dose of MK-0941 will be administered in each period intervention 2: a single oral placebo will be administered in the designated period (Periods 1-5)

Protocol document: